Fetal safety of erythromycin. An update of Swedish data

European Journal of Clinical Pharmacology

Volumn 70, Issue 3, 2014, Pages 355-360

  Källén, Bengt ^a   Danielsson, Bengt R ^b  

^a UNIVERSITY OF LUND   (Sweden)

^b NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

Author keywords

Cardiovascular defects; Erythromycin; Macrolides; Pregnancy

Indexed keywords

ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTER, FIRST; REGISTRIES; RISK; SWEDEN;

EID: 84894435293     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1624-3     Document Type: Article

References (17)

1. Källén BAJ, Otterblad OP (2003) Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17:255-261
2. Källén BAJ, Otterblad Olausson P, Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20:209-214
3. Källén KBM (2005) Maternal drug use in early pregnancy and risk of cardiovascular defect in infant - A follow-up study. Reprod Toxicol 26:64-65
4. Cooper WO, Harnandez-Diaz S, Arbogast PG, Dudley JA, Dyer SM, Gideon PS, Hall KS, Kaltenbach LA, Ray WA (2008) Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol 23:18-28
5. Romøren M, Lindbæck M, Nordeng H (2012) Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol 74:1053-1062
6. Dinur AB, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R, Levy A (2013) Fetal safety of macrolides. Antimicrob Agents Chemother 57:3307-3311
7. National Board of Health and Welfare (2003) Centre for Epidemiology. The Swedish Medical Birth Register - a summary of content and quality. (http://www.socialstyrelsen.se/Publikationer2003/2003-112-3)
8. Källén B, Otterblad Olausson P (2001) Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias? Int J Risk Saf Med 14:115-119
9. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M (2007) The new Swedish prescribed drug register - Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726-735
10. National Board of Health and Welfare (2004) Centre for Epidemiology. Registration of congenital malformations in Swedish health registers. (http://www.socialstyrelsen.se/Publikationer2004/2004-112-1)
11. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ (2009) Antibacterial medication during pregnancy and risk of birth defects. National Birth Defects Prevention Study. Arch Pediatr Adolesc Med 163:978-985
12. Lin KJ, Mitchell AA, Yau W-P, Louik C, Hernández-Diaz S (2013) Safety of macrolides during pregnancy. Am J Obstet Gynecol 208(221e):e1-e8
13. Källén B, Otterblad Olausson P (2007) Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infant. Eur J Clin Pharmacol 63:383-388
14. Källén B (2009) Drugs during Pregnancy. Nova Biomedical Books, New York
15. Danielsson BR, Danielsson C, Nilsson MF (2007) Embryonic cardiac arrhythmia and generation of reactive oxygen species: common teratogenic mechanism for IKr blocking drugs. Reprod Toxicol 24:42-56
16. Sköld A-C, Wellfelt K, Danielsson BR (2001) Stage-specific skeletal and visceral defects of the Ikr-blocker almokalant: Further evidence for teratogenicity via a hypoxia-related mechanism. Teratology 64:292-300
17. Danielsson C, Brask J, Sköld AC, Genead R, Andersson A, Andersson U, Stockling K, Pehrson R, Grinnemo KH, Salari S, Hellmold H, Danielsson B, Sylvén C, Elinder F (2013) Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism. Cardiovasc Res 97:23-32